Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02257174

Publication Date:

March 3, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Human Chorionic Gonadotrophin (HCG) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Human Chorionic Gonadotrophin (HCG) is a hormone produced during pregnancy. It is used as an indicator in pregnancy tests and can also be administered medically for various purposes.
United States market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Human Chorionic Gonadotrophin (HCG) players cover Qingdao Kangyuan Pharmaceutical Co., Ltd., Ningbo Renjian Pharmaceutical Group Co., Ltd., Jiangxi Haoran Biopharmaceutical Co., Ltd., Shanghai Tianwei Biopharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淗uman Chorionic Gonadotrophin (HCG) Industry Forecast鈥� looks at past sales and reviews total world Human Chorionic Gonadotrophin (HCG) sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Chorionic Gonadotrophin (HCG) sales for 2025 through 2031. With Human Chorionic Gonadotrophin (HCG) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Chorionic Gonadotrophin (HCG) industry.
This Insight Report provides a comprehensive analysis of the global Human Chorionic Gonadotrophin (HCG) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human Chorionic Gonadotrophin (HCG) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Human Chorionic Gonadotrophin (HCG) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Chorionic Gonadotrophin (HCG) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Chorionic Gonadotrophin (HCG).
This report presents a comprehensive overview, market shares, and growth opportunities of Human Chorionic Gonadotrophin (HCG) market by product type, application, key players and key regions and countries.
Segmentation by Type:
u-hCG
r-hCG
Segmentation by Application:
Drug
Pregnancy Test Paper
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Qingdao Kangyuan Pharmaceutical Co., Ltd.
Ningbo Renjian Pharmaceutical Group Co., Ltd.
Jiangxi Haoran Biopharmaceutical Co., Ltd.
Shanghai Tianwei Biopharmaceutical Co., Ltd.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2020-2031)
2.1.2 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Human Chorionic Gonadotrophin (HCG) by Country/Region (2020, 2024 & 2031)
2.2 Human Chorionic Gonadotrophin (HCG) Segment by Type
2.2.1 u-hCG
2.2.2 r-hCG
2.3 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Type
2.3.1 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Human Chorionic Gonadotrophin (HCG) Segment by Application
2.4.1 Drug
2.4.2 Pregnancy Test Paper
2.4.3 Other
2.5 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Application
2.5.1 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Player
3.1 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Human Chorionic Gonadotrophin (HCG) Revenue by Player (2020-2025)
3.1.2 Global Human Chorionic Gonadotrophin (HCG) Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Human Chorionic Gonadotrophin (HCG) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Human Chorionic Gonadotrophin (HCG) by Region
4.1 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Region (2020-2025)
4.2 Global Human Chorionic Gonadotrophin (HCG) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size Growth (2020-2025)
4.4 APAC Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size Growth (2020-2025)
4.5 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2020-2025)
5.2 Americas Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Type (2020-2025)
5.3 Americas Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Region (2020-2025)
6.2 APAC Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Type (2020-2025)
6.3 APAC Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2020-2025)
7.2 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Type (2020-2025)
7.3 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Chorionic Gonadotrophin (HCG) by Region (2020-2025)
8.2 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Forecast
10.1 Global Human Chorionic Gonadotrophin (HCG) Forecast by Region (2026-2031)
10.1.1 Global Human Chorionic Gonadotrophin (HCG) Forecast by Region (2026-2031)
10.1.2 Americas Human Chorionic Gonadotrophin (HCG) Forecast
10.1.3 APAC Human Chorionic Gonadotrophin (HCG) Forecast
10.1.4 Europe Human Chorionic Gonadotrophin (HCG) Forecast
10.1.5 Middle East & Africa Human Chorionic Gonadotrophin (HCG) Forecast
10.2 Americas Human Chorionic Gonadotrophin (HCG) Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.2.2 Canada 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.2.3 Mexico 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.2.4 Brazil 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.3 APAC Human Chorionic Gonadotrophin (HCG) Forecast by Region (2026-2031)
10.3.1 China Human Chorionic Gonadotrophin (HCG) 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.3.3 Korea 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.3.4 Southeast Asia 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.3.5 India 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.3.6 Australia 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.4 Europe Human Chorionic Gonadotrophin (HCG) Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.4.2 France 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.4.3 UK 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.4.4 Italy 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.4.5 Russia 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.5 Middle East & Africa Human Chorionic Gonadotrophin (HCG) Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.5.2 South Africa 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.5.3 Israel 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.5.4 Turkey 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
10.6 Global Human Chorionic Gonadotrophin (HCG) Forecast by Type (2026-2031)
10.7 Global Human Chorionic Gonadotrophin (HCG) Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Human Chorionic Gonadotrophin (HCG) Forecast
11 Key Players Analysis
11.1 Qingdao Kangyuan Pharmaceutical Co., Ltd.
11.1.1 Qingdao Kangyuan Pharmaceutical Co., Ltd. Company Information
11.1.2 Qingdao Kangyuan Pharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Product Offered
11.1.3 Qingdao Kangyuan Pharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Qingdao Kangyuan Pharmaceutical Co., Ltd. Main Business Overview
11.1.5 Qingdao Kangyuan Pharmaceutical Co., Ltd. Latest Developments
11.2 Ningbo Renjian Pharmaceutical Group Co., Ltd.
11.2.1 Ningbo Renjian Pharmaceutical Group Co., Ltd. Company Information
11.2.2 Ningbo Renjian Pharmaceutical Group Co., Ltd. Human Chorionic Gonadotrophin (HCG) Product Offered
11.2.3 Ningbo Renjian Pharmaceutical Group Co., Ltd. Human Chorionic Gonadotrophin (HCG) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Ningbo Renjian Pharmaceutical Group Co., Ltd. Main Business Overview
11.2.5 Ningbo Renjian Pharmaceutical Group Co., Ltd. Latest Developments
11.3 Jiangxi Haoran Biopharmaceutical Co., Ltd.
11.3.1 Jiangxi Haoran Biopharmaceutical Co., Ltd. Company Information
11.3.2 Jiangxi Haoran Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Product Offered
11.3.3 Jiangxi Haoran Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Jiangxi Haoran Biopharmaceutical Co., Ltd. Main Business Overview
11.3.5 Jiangxi Haoran Biopharmaceutical Co., Ltd. Latest Developments
11.4 Shanghai Tianwei Biopharmaceutical Co., Ltd.
11.4.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information
11.4.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Product Offered
11.4.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Main Business Overview
11.4.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.